Jagsonpal Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals has published its unaudited financial results for the quarter and half year ended September 30, 2025 in Business Standard (English and Hindi editions) as required by SEBI listing rules. Total income from operations stood at Rs. 774.92 million in Q2 FY26 versus Rs. 763.46 million in Q2 FY25, a marginal ~1.5% year-on-year growth. Profit after tax rose to Rs. 125.74 million in Q2 FY26 compared to Rs. 114.59 million in Q2 FY25, up about 10%. For the half year, total income grew ~12% to Rs. 1,559.29 million while profit after tax jumped ~39% to Rs. 233.69 million. Basic EPS for H1 FY26 stood at Rs. 3.50 versus Rs. 2.52 in H1 FY25. Results were reviewed by the audit committee and approved by the board.
The filing itself is just a regulatory newspaper publication of already-filed results, so it is unlikely to move the stock. However, the underlying numbers show healthy profit growth, particularly at the half-year level, which is mildly positive for shareholders.